Communicable Diseases Branch

NSW VACCINE PREVENTABLE DISEASE ANNUAL REPORT

2017
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LHD</td>
<td>Local Health Districts</td>
<td>NS</td>
<td>Northern Sydney LHD</td>
</tr>
<tr>
<td>CC</td>
<td>Central Coast LHD</td>
<td>PHU</td>
<td>Public health unit</td>
</tr>
<tr>
<td>FW</td>
<td>Far West LHD</td>
<td>SES</td>
<td>South Eastern Sydney LHD</td>
</tr>
<tr>
<td>HNE</td>
<td>Hunter New England LHD</td>
<td>SNSW</td>
<td>Southern NSW LHD</td>
</tr>
<tr>
<td>IS</td>
<td>Illawarra Shoalhaven LHD</td>
<td>SWS</td>
<td>South Western Sydney LHD</td>
</tr>
<tr>
<td>M</td>
<td>Murrumbidgee LHD</td>
<td>SYD</td>
<td>Sydney LHD</td>
</tr>
<tr>
<td>MNC</td>
<td>Mid North Coast LHD</td>
<td>WNSW</td>
<td>Western NSW LHD</td>
</tr>
<tr>
<td>NBM</td>
<td>Nepean Blue Mountains LHD</td>
<td>WS</td>
<td>Western Sydney LHD</td>
</tr>
<tr>
<td>NIP</td>
<td>National Immunisation Program</td>
<td>NSW</td>
<td>New South Wales</td>
</tr>
<tr>
<td>NNSW</td>
<td>Northern NSW LHD</td>
<td>VPD</td>
<td>Vaccine preventable diseases</td>
</tr>
</tbody>
</table>
Summary

This annual report aims to describe the epidemiology of selected vaccine preventable diseases in New South Wales, Australia for the year 2017. Publishing regular epidemiological updates enables the identification of trends both nationally and internationally, informing ongoing disease surveillance and control efforts.

Conditions included in the report are: diphtheria, invasive *Haemophilus influenzae* type b disease, measles, mumps, invasive meningococcal disease, pertussis, invasive pneumococcal disease, rubella and tetanus.

Most vaccine preventable diseases in NSW remain well controlled with a low and stable level of notifications occurring each year. However control of pertussis remains a persistent challenge.

2017 vaccine preventable disease trends

- Hib cases increased slightly compared to the previous 3 years, but remain rare in NSW

- Invasive meningococcal disease notifications continued to increase, however cases caused by serogroup W were slightly lower than 2016. Serogroup B continues to be the predominant strain in NSW.

- Measles cases increased in 2017 (n=30) compared to 2016 (n=18) due to a number of small outbreaks associated with importations from overseas. Gentoype D8 continued to predominate.

- Mumps notifications doubled compared to 2016, possibly related to a national increase in mumps.

- Pertussis notifications in NSW saw a steady decrease throughout 2017, with numbers in December reaching the lowest seen since September 2014.

- Rubella, tetanus, and diphtheria, remain rare and well controlled in NSW.
Introduction

Under the New South Wales (NSW) Public Health Act 2010, certain conditions are required to be notified to public health authorities in NSW. Notification of conditions allows for a coordinated public health response to minimise the risk to the community and to limit onward spread of the disease. Furthermore, disease surveillance allows for epidemiological analysis of notification data, facilitating the identification of patterns and trends which can inform public health policy. Monitoring of vaccine preventable disease allows an assessment of the effectiveness of vaccine programs and can inform subsequent public health action.

This report is part of a yearly series examining NSW epidemiology. Description of the NSW health system and Australian vaccination schedule has been published previously (1). In NSW there are 15 local health districts (LHD) with 12 public health units (PHU). Public health management is conducted at a local level and coordinated centrally by the Communicable Disease Branch, Health Protection NSW.

Australia’s National Immunisation Program (NIP) is funded by the Australian Government and administered by states and territories (2) who are also responsible for public health follow up of notifiable conditions (3). Immunisation campaigns can also be initiated and funded at a state level, in response to local conditions. Since 2015, NSW has funded a maternal pertussis vaccination program in response to increasing notifications first observed in 2014 and new evidence on the effectiveness of vaccination during pregnancy in protecting infants during the early months of life (4). In 2017, in response to ongoing increases in cases of invasive meningococcal disease caused by a hypervirulent meningococcal serogroup W strain, the NSW Meningococcal W Response Program was launched, providing free Meningococcal ACWY vaccine to NSW secondary students in years 11 and 12 via the NSW School-based Vaccination Program.

Conditions included in the report are: diphtheria, invasive Haemophilus influenzae type b disease, measles, mumps, invasive meningococcal disease, pertussis, invasive pneumococcal disease, rubella and tetanus.

Some other vaccine preventable conditions are also notifiable in NSW including cholera, typhoid, hepatitis A and rotavirus; Q fever; hepatitis B; and influenza infections. Reports on these conditions can be found in the OzFoodNet, Zoonoses, Sexually Transmitted Infections and Influenza Reports. Polio is also notifiable, however, Australia was officially declared polio free on October 29, 2000, with not a single locally acquired case reported since 1972. Chicken pox and shingles are vaccine preventable, but not notifiable in NSW, however emergency department presentations of these conditions are reported (http://www.health.nsw.gov.au/Infectious/Pages/data.aspx)

Methods are presented in appendix 1, rates by year appendix 2
Diphtheria

Diphtheria is a contagious and potentially life-threatening bacterial infection caused by toxin-producing strains of *Corynebacterium diphtheriae*. Diphtheria was a common cause of death in children up until the 1940s but now has almost disappeared in Australia as a result of immunisation, with fewer than four cases notified nationally each year since 1991.

Diphtheria occurs when toxigenic *Corynebacterium diphtheriae* infect the back of the throat. The toxin formed by the diphtheria bacteria can cause inflammation of heart muscle and nerves that can be fatal, with death occurring in 5-10% of cases.

*Corynebacterium diphtheriae* bacteria can also cause skin infections resulting in a poorly healing ulcer. Not all strains of *Corynebacterium diphtheriae* produce the toxin, and public health units receive notifications of skin infections caused by non-toxigenic *Corynebacterium diphtheriae* from time to time. Skin infections caused by toxin-producing strains are potentially serious in unvaccinated people because of the effects of the toxin on the heart and nervous system. Cutaneous diphtheria is more common in the tropics than in areas where the climate is more temperate.

Diphtheria vaccine is provided as part of the NIP and in 2017 was provided as a part of a combination vaccine at 6 weeks, 4 and 6 months of age, with booster doses at 18 months, and 4 and 12 years of age. The vaccine protects against the toxin produced by the bacterium, so vaccinated people can have infection with *Corynebacterium diphtheriae* but are unlikely to suffer the effects of the toxin.

**Summary 2017**

- Case count: 0
**Haemophilus influenzae type b**

*Haemophilus influenzae* type b disease (Hib) is caused by infection with *Haemophilus influenzae* type b bacteria. Humans are the only known reservoir, and the organism can be carried asymptomatically in the naso- and oro-pharynx. Hib is predominantly transmitted from asymptomatic carriers by direct contact with respiratory droplets or discharges from the nose and throat. It can also rarely be transmitted from infected persons. Hib does not survive in the environment on inanimate surfaces.

Infection can lead to serious illness including meningitis and epiglottitis (inflammation of the throat). Since Hib vaccines were included in the routine childhood immunisation schedule in 1993, there has been a reduction of more than 95% in notified cases of Hib. In 2017 four doses of Hib vaccine were recommended in NSW for all infants at 6 weeks, 4, 6 and 12 months of age and provided as part of free routine immunisation in combination vaccines due at those ages.

### Summary 2017
- **Case count:** 9
- **Reported deaths:** 2
- **Notification rate 0.11 per 100,000**

**Overall trend:**
- Rare in NSW
- Remains at a stable rate

**Seasonality:**
- Sporadic

**Vaccination status of cases**
- Three cases (adults) were not vaccinated
- Three children fully vaccinated for age, one partially vaccinated
- Two infants were vaccinated for age

![Notifications of Hib 2003 to 2017](image)

**Figure 1.** Notifications of Hib 2003 to 2017.
Invasive meningococcal disease (IMD) is caused by infection with one of several serogroups of *Neisseria meningitidis* bacteria. The bacteria are spread through direct contact of mucous membranes with the organism, such as exposure to respiratory droplets from the nose and throat of a person carrying the organism. Close contact may result in the bacteria colonising the throat of the exposed person but in most people this does not cause any disease. In only a very small proportion of people the bacteria may invade from the throat to other parts of the body, causing IMD.

IMD typically involves meningitis (infection of the lining of the brain), septicaemia (infection of the blood) or both. Up to 10 per cent of IMD infections are fatal even with appropriate antibiotic treatment, and survivors may be left with long-term complications. There are several serogroups of *Neisseria meningitidis* which can cause invasive disease. The common serogroups in Australia are B, C, W and Y.

Notifications of IMD have been increasing in NSW since 2015; largely due to increases in cases caused by serogroup W. This pattern has also been observed across the rest of Australia. Cases caused by serogroup W tend to be more severe and are associated with a higher case fatality rate. The situation continues to be closely monitored.

Total notifications for IMD in 2017 (n=91) were higher than in 2016 (n=71), however cases caused by serogroup W were slightly lower (Figure 2.). Serogroup B continues to be the predominant strain in NSW, accounting for 47% of cases (n=43).

Meningococcal C vaccine has been routinely provided as part of the NIP since 2003, and is administered at 12 months of age. In 2017 in response to the increase in cases caused by serogroup W, NSW implemented the NSW Meningococcal W Response Program, which provided free meningococcal A, C, W, Y vaccine to students in years 11 and 12 via the School Immunisation Program. Vaccine was also provided free to individuals aged 17-19, not enrolled in school, via GPs. This program will continue into 2018, targeting students in years 10 and 11.

### Summary 2017

- **Case count:** 91
- **Reported deaths:** 5
  - Serogroups B (2), C (1), Y(2)
- **Notification rate** 1.16 per 100,000

**Overall trend:**
- Rare, but increasing

**Seasonality:**
- Increase late winter/early spring

**Age distribution:**
- All age groups affected
  - 15 cases (16%) in infants
  - 24 cases (26%) 15-24 yrs

**Vaccination status of cases**
- 22 vaccinated, but not against infecting strain
- 69 not vaccinated or unable to recall vaccination status.
Invasive meningococcal disease (continued)

Figure 2. Invasive meningococcal disease notifications by serogroup 2008 to 2017

Figure 3. Age and sex distribution for invasive meningococcal disease notifications in 2017.
Invasive pneumococcal disease

Invasive pneumococcal disease (IPD) is caused by the bacterium *Streptococcus pneumoniae*. It can cause a variety of presentations including pneumonia, septicaemia (blood infection), otitis media and meningitis. Symptoms depend on the site of infection and the age of the person. People with pneumococcal pneumonia tend to experience shortness of breath, fever, lack of energy, loss of appetite, headache, chest pain and cough.

People most at risk of the infection include children under two years of age, older adults, Aboriginal people, people with lung disease, heart disease, cancer, kidney disease, or HIV infection, people whose spleen has been removed or is impaired, and people who smoke.

There are over 90 serotypes of pneumococcal bacteria. Different pneumococcal serotypes vary in their propensity to cause disease. The current pneumococcal vaccine used for children under the NIP - Prevenar 13® - covers the 13 serotypes most commonly associated with invasive disease, and in 2017 was given in NSW at 6 weeks, 4 and 6 months of age. Adults with risk factors for IPD, Aboriginal people 50 years and over, and other adults 65 years of age and older are eligible for vaccination with Pneumovax 23®, a vaccine which covers 23 serotypes. Under the NIP people in these groups are eligible for one dose, with a second due 5 years later for Aboriginal people and those that have an underlying medical condition.

### Summary 2017

- Case count: 694
- Reported deaths: 64
- Notification rate 8.8 per 100,000

Overall trend:
- Increasing

Seasonality:
- Increase during winter flu season

Age distribution:
- 13% of cases under 5 years of age
- 69% of cases 50 years or over

Vaccination status of cases:
- 91% of cases under 5 years old had received at least one dose of pneumococcal vaccine. Seventy nine percent of cases were fully vaccinated, of these 52% were infected with a serotype not covered by the vaccine
- 29% of cases aged >50 years had received at least one dose of the 23 valent pneumococcal vaccine, of these 49% were infected with a serotype not included in the vaccine
Invasive pneumococcal disease (continued)

Figure 4. Monthly notifications of IPD by age group, 2015 to 2017.

Six hundred and ninety four cases of IPD were notified in 2017, a 27% increase compared to 2016 (Table 1). The increased number of cases in 2017 is probably related to the severe influenza season that year. Sixty-four deaths were identified, one was in a fully vaccinated one year old (no typing available). Of the remaining deaths, 13 were in the 50 to 64 year age group and 50 deaths were in people aged 65 years or older.

Of the 576 cases that occurred in the age groups which are followed up by PHUs (0 to 4 year age group, and 50 years or over), 18 (3%) were notified in Aboriginal people, amongst whom case notification rates were higher than in non-Aboriginal people (27.7 and 17.4 per 100,000, respectively).

Figure 5. Age and sex distribution of IPD notifications in 2017.
Rates of disease by LHD varied from 5.3 cases per 100,000 population in Northern Sydney LHD to 12.9 cases per 100,000 population in Western NSW LHD (Figure 4).

The rate of IPD in children under five years of age was 12.9 cases per 100,000 population, up from the previous year (11.8 cases per 100,000). Most of the notifications were in adults (Figure 5). Serotype 3 (N=14) and 19A (N=10) were the leading cause of all disease in children (34%), both of which are included in the current 13-valent vaccine. In children under five years of age, 52% of disease was caused by non-vaccine serotypes and this proportion continues to increase. Vaccination data was available for 99% (87 cases) of notifications under the age of five years. Sixty-nine (79%) cases were fully vaccinated and 15 (17%) cases were either partially vaccinated or were too young to have received their first dose. There were 3 (4%) cases whose parents chose not to vaccinate. There were 28 (41%) cases of vaccine serotype disease in fully vaccinated children (i.e. vaccine failure). Serotype 3 accounted for 50% of vaccine failures, while serotypes 19A (29%), 19F (18%), and 18C (3%) were responsible for the remainder of cases. The number of vaccine failures in children less than five years was notably increased compared to the previous year (28 vs 15 cases) but the proportions by serotype were similar to those in 2016.
The measles virus is highly infectious and it is readily transmitted from person to person via respiratory secretions in the air following coughing and sneezing. Symptoms of measles include fever, runny nose, sore red eyes and cough. This is followed three to four days later by a red blotchy rash spreading from the head and neck to the rest of the body.

Infection with measles can cause more serious complications such as middle ear infection, or pneumonia affecting the small airways of the lungs and more rarely, encephalitis (swelling of the brain). Subacute sclerosing panencephalitis is a very rare, chronic, fatal, brain inflammation, which occurs years after infection in one per 100,000 cases.

Measles containing vaccine (MCV) is routinely offered to all children at 12 months (as measles-mumps-rubella (MMR)) and 18 months of age (as measles-mumps-rubella-varicella (MMRV)) through the NIP, and is available for free in NSW for anyone born during or after 1966 who does not have documented evidence of two doses of MCV.

Measles cases increased in 2017 (n=30) compared to 2016 (n=18) due to a number of small outbreaks associated with importations from overseas. Travellers are encouraged to discuss travel plans with their GP, as measles remains endemic in many areas of the world, including South East and Southern Asia. People without two documented doses of MCV may require vaccination prior to travel. Parents of children planning travel should discuss travel plans with their doctor as the first dose of MMR can be given at 9 months of age to children travelling to areas with endemic measles or measles.

Overall trend:
- Rare in NSW (eliminated)
- Low numbers of sporadic cases

Seasonality
- Sporadic

Age distribution:
- Four infants
- Five cases aged 1-14 yrs
- Seven cases 15 yrs and older

Summary 2017
- Case count: 30
- Reported deaths: 0
- Notification rate 0.38 per 100,000

Place of acquisition
- Eight importations from overseas
  - Five from S.E Asia
  - Two from Southern Asia
  - One from Europe
- 21 acquired in Australia
  - 20 in NSW
  - One in Victoria
- One unknown

Genotyping:
- Four Genotype B3 (SE.Asia strain)
- 19 Genotype D8 (Sth Asia strain)

Vaccination status of cases
- Four too young to be vaccinated
- Two partially vaccinated
- One fully vaccinated
- Two vaccinated, number of doses unknown
- 21 not vaccinated or unable to recall vaccination status
Figure 7. Measles notifications 2003 to 2017

Figure 8. Age and sex distribution measles notifications 2017
**Mumps**

Mumps is an acute viral disease. Common symptoms include fever, loss of appetite, tiredness and headaches followed by swelling and tenderness of the salivary glands. Complications are rare but can be serious including encephalitis and meningitis, orchitis (infection of the testes), spontaneous abortion and hearing loss. The mumps virus is transmitted through contact with respiratory secretions; usually from respiratory droplets through the airborne route but also through direct contact with the saliva of an infected person.

Mumps is a vaccine preventable disease, and notifiable in NSW. Vaccination against mumps is with the measles-mumps-rubella (MMR) and measles-mumps-rubella-varicella (MMRV) vaccine, given as part of the NIP and scheduled at 12 and 18 months of age respectively.

Mumps cases in NSW increased in 2017 with twice as many cases as 2016. This increase may be related to increased exposure to the mumps virus because of outbreaks in other Australian states and territories in 2017.

**Summary 2017**

- Case count: 127
- Reported deaths: 0
- Notification rate 1.62 per 100,000

- Periodic increases

**Seasonality:**

- Sporadic in NSW

**Age distribution:**

- 104 cases aged 15 years and over
- 23 cases under the age of 15

**Vaccination status of cases**

- 49 reported as vaccinated
  - 23 confirmed to be vaccinated fully for age
- 64 unvaccinated or unable to recall vaccination status

**Figure 8.** Mumps notifications 2003 to 2017
Pertussis

Pertussis, also known as 'whooping cough', is a highly contagious bacterial infection affecting the respiratory system caused by the bacterium *Bordetella pertussis*. It affects individuals of all ages, but is more severe (and can be fatal) in small babies, particularly those too young to be vaccinated or those who are unvaccinated. Elderly people are also at increased risk of developing complications from pertussis.

Although pertussis is a vaccine preventable disease, epidemics can occur every 3 or 4 years despite high vaccination rates due to incomplete protection from the vaccine and waning immunity from both infection and vaccination. Waning immunity refers to a person’s progressive loss of protective antibodies against a disease over time, requiring administration of another dose of vaccine (booster). In 2017 under the NIP Schedule vaccination against pertussis was with a combination vaccine given at 6 weeks, 4 and 6 months, with booster doses at 18 months and 4 and 12 years of age.

To protect infants too young to be vaccinated, the NSW Antenatal Pertussis Vaccination Program continued in 2017, offering free diphtheria, tetanus and pertussis (dTpa – Boostrix®) vaccine to all pregnant women in the third trimester of pregnancy, preferably at 28 weeks gestation. As there is placental transfer of maternal pertussis antibody to the fetus, infants acquire immunity that protects them during the period before they are old enough to be vaccinated at six weeks of age.

Pertussis notifications in NSW saw a steady decrease throughout 2017, with numbers in December (n=314) reaching the lowest seen since September 2014 (n= 319).

<table>
<thead>
<tr>
<th>Summary 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Case count: 5274</td>
</tr>
<tr>
<td>• Reported deaths: 0</td>
</tr>
<tr>
<td>• Notification rate 67.1 per 100,000</td>
</tr>
</tbody>
</table>

Overall trend:

• Common in NSW

• Periodic epidemics every three to four years

Seasonality:

• Highest notifications from late winter to early summer

Age distribution:

• 205 cases aged less than 1 year

• 737 cases aged 1-4 years old

• 4332 cases 5 years and older

• Adult numbers may be underreported compared to children because adults are not routinely followed up by PHUs to allow case confirmation.

Vaccination status of cases

• In the 0 to 4 age group – for which routine follow up occurs – 89 % were recorded as having received a vaccine for this condition. Of these, 90% were fully vaccinated for age
**Figure 9.** Pertussis notifications 2008 to 2017 by month of onset.

**Figure 10.** Age and sex distribution of pertussis notifications 2017.
Rubella

Rubella is a viral infection causing mild symptoms including fever and a transient rash. Rubella infection of the mother during pregnancy can result in the fetus also becoming infected, causing congenital rubella syndrome. Abnormalities occur in up to 90% of infants born to women who had rubella during the first trimester of pregnancy. Abnormalities include intellectual disabilities, cataracts, deafness, heart abnormalities, intrauterine growth retardation, and inflammatory lesions of the brain, liver, lungs, and bone marrow.

Vaccination against rubella is with the measles-mumps-rubella (MMR) and measles-mumps-rubella-varicella (MMRV) vaccine, is given as part of the National Immunisation Program and scheduled at 12 and 18 months of age respectively.

<table>
<thead>
<tr>
<th>Summary 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Case count:</strong> 6</td>
</tr>
<tr>
<td><strong>Reported deaths:</strong> 0</td>
</tr>
<tr>
<td><strong>Notification rate 0.08 per 100,000</strong></td>
</tr>
</tbody>
</table>

**Overall trend:**
- Rare in NSW

**Seasonality:**
- Sporadic

**Age distribution:**
- Two cases in children 5-15 years
- Four cases in adults
  - 2 cases in females of child bearing age

**Vaccination status of cases**
- Two vaccinated
  - One child
  - One female of child bearing age
- Four unvaccinated or unable to recall their vaccination status

**Figure 11.** Rubella notifications 2003 to 2017
Tetanus

Tetanus is caused by the bacterium *Clostridium tetani*, an organism which is commonly found in soil, dust and animal faeces. Disease occurs when the organism enters the body through a break in the skin (such as a puncture wound). When the bacterium grows it produces a neurotoxin which causes involuntary muscle contraction; the disease can be life threatening. Tetanus is not transmitted between people.

Infection may occur after minor injury to the skin that is contaminated with soil, dust or manure or after major injuries and burns. Symptoms of the disease usually develop 3 to 21 days after exposure but the onset can sometimes be delayed for several months. Toxin produced by the bacteria attack the central nervous system causing muscle rigidity with painful spasms, including the characteristic muscle spasms of the jaw ("lock jaw").

In 2017, tetanus vaccine was given in combination vaccines at 6 weeks, 4 and 6 months of age, with boosting doses at 18 months, and 4 and 12 years of age. Adults who haven't had a booster in the last ten years should also get a dose.

**Summary 2017**

- Case count: 1
- Reported deaths: 0
- Notification rate 0.01 per 100,000

**Overall trend:**

- Rare in NSW
- Remains at a stable rate

**Seasonality:**

- Sporadic

**Age distribution:**

- 05-09 years

**Vaccination status of cases**

- The case was not vaccinated

---

**Figure 12.** Tetanus notification 2003 to 2017.
Method

Disease notifications for: diphtheria, invasive *Haemophilus influenzae* serotype b disease, measles, mumps, invasive meningococcal disease, pertussis, invasive pneumococcal disease, rubella and tetanus were included if they had a recorded onset in 2017 and met the national case definition (3).

Crude notification rates per 100,000 population were calculated for year of notification (1991 to 2017) age group and LHD. Population estimates used were from Health Stats NSW (5).

Notifications were analysed by age, sex, vaccination status and geographic residence where information was available.

Notifications are counted as NSW cases where the address of residence:
- is in NSW or
- is overseas, and the diagnosis was made in NSW.
### Appendix 2

Notification and rate per 100,000 population by year onset for selected conditions

<table>
<thead>
<tr>
<th>Year of onset</th>
<th>Haemophilus influenzae type b</th>
<th>Measles</th>
<th>Meningococcal Disease</th>
<th>Mumps</th>
<th>Pertussis</th>
<th>Pneumococcal Disease (Invasive)</th>
<th>Rubella</th>
<th>Tetanus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Rate</td>
<td>N</td>
<td>Rate</td>
<td>N</td>
<td>Rate</td>
<td>N</td>
<td>Rate</td>
</tr>
<tr>
<td>2017</td>
<td>9</td>
<td>0.11</td>
<td>30</td>
<td>0.38</td>
<td>91</td>
<td>1.16</td>
<td>127</td>
<td>1.62</td>
</tr>
<tr>
<td>2016</td>
<td>5</td>
<td>0.06</td>
<td>18</td>
<td>0.23</td>
<td>71</td>
<td>0.92</td>
<td>67</td>
<td>0.87</td>
</tr>
<tr>
<td>2015</td>
<td>5</td>
<td>0.07</td>
<td>9</td>
<td>0.12</td>
<td>44</td>
<td>0.58</td>
<td>63</td>
<td>0.83</td>
</tr>
<tr>
<td>2014</td>
<td>6</td>
<td>0.08</td>
<td>67</td>
<td>0.89</td>
<td>37</td>
<td>0.49</td>
<td>79</td>
<td>1.05</td>
</tr>
<tr>
<td>2013</td>
<td>9</td>
<td>0.12</td>
<td>34</td>
<td>0.46</td>
<td>46</td>
<td>0.62</td>
<td>91</td>
<td>1.23</td>
</tr>
<tr>
<td>2012</td>
<td>2</td>
<td>0.03</td>
<td>170</td>
<td>2.33</td>
<td>65</td>
<td>0.89</td>
<td>106</td>
<td>1.45</td>
</tr>
<tr>
<td>2011</td>
<td>4</td>
<td>0.06</td>
<td>90</td>
<td>1.25</td>
<td>71</td>
<td>0.98</td>
<td>68</td>
<td>0.94</td>
</tr>
<tr>
<td>2010</td>
<td>6</td>
<td>0.08</td>
<td>25</td>
<td>0.35</td>
<td>73</td>
<td>1.02</td>
<td>40</td>
<td>0.56</td>
</tr>
<tr>
<td>2009</td>
<td>6</td>
<td>0.09</td>
<td>19</td>
<td>0.27</td>
<td>92</td>
<td>1.3</td>
<td>40</td>
<td>0.57</td>
</tr>
<tr>
<td>2008</td>
<td>8</td>
<td>0.12</td>
<td>39</td>
<td>0.56</td>
<td>80</td>
<td>1.15</td>
<td>77</td>
<td>1.11</td>
</tr>
<tr>
<td>2007</td>
<td>7</td>
<td>0.1</td>
<td>4</td>
<td>0.06</td>
<td>109</td>
<td>1.59</td>
<td>323</td>
<td>4.73</td>
</tr>
<tr>
<td>2006</td>
<td>11</td>
<td>0.16</td>
<td>60</td>
<td>0.89</td>
<td>101</td>
<td>1.5</td>
<td>155</td>
<td>2.3</td>
</tr>
<tr>
<td>2005</td>
<td>7</td>
<td>0.1</td>
<td>5</td>
<td>0.07</td>
<td>137</td>
<td>2.05</td>
<td>111</td>
<td>1.66</td>
</tr>
<tr>
<td>2004</td>
<td>5</td>
<td>0.08</td>
<td>11</td>
<td>0.17</td>
<td>146</td>
<td>2.2</td>
<td>65</td>
<td>0.98</td>
</tr>
<tr>
<td>2003</td>
<td>6</td>
<td>0.09</td>
<td>17</td>
<td>0.26</td>
<td>197</td>
<td>2.98</td>
<td>36</td>
<td>0.54</td>
</tr>
</tbody>
</table>